{
  "abstract": "Introduction\n\nAmyloid-related imaging abnormalities (ARIA) are a major safety concern in anti-amyloid therapy for Alzheimer's disease (AD), but real-world data remain limited. We investigated risk factors, temporal characteristics, and spatial distribution of ARIA in aducanumab-treated patients and assessed the safety of apolipoprotein E (APOE) genotype-tailored dosing.Methods\n\nWe retrospectively analyzed 168 patients with a Clinical Dementia Rating (CDR) of 0.5 to 2 treated with aducanumab between 2022 and 2024. Dosing was individualized by APOE genotype. Serial magnetic resonance imaging (MRI) detected ARIA, multivariable regression identified risk factors, and ARIA with edema or effusion (ARIA-E) lesions were manually segmented to generate topographical maps.Results\n\nAmong 164 patients, 33 (20.1%) developed ARIA-E, with incidence increasing by APOE ε4 status (12.5% non-carriers, 19.5% heterozygotes, 50.0% homozygotes; p = 0.002). Lesions showed posterior predominance. Independent risk factors included APOE ε4 homozygosity, CDR 2, and hypertension. Most cases did not require treatment discontinuation.Discussion\n\nARIA-E risk during aducanumab therapy was influenced by genetic and clinical factors, supporting genotype-tailored titration in practice.",
  "abstract_shown": true,
  "affiliations": [
    "Alzheimer's Disease Convergence Research Center Samsung Medical Center Seoul Republic of Korea.",
    "Department of Neurology Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Republic of Korea.",
    "Happymind Clinic Seoul Republic of Korea.",
    "Human Medical Imaging and Intervention Center Seoul Republic of Korea.",
    "Department of Radiology Gangneung Asan Hospital University of Ulsan College of Medicine Gangneung Republic of Korea.",
    "Beaubrain Healthcare Inc. Seoul Republic of Korea."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Soyeon Yoon"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Jehyun Ahn"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Seongmi Kim"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Kyoungmin Kim"
    },
    {
      "affs": [
        2
      ],
      "name": "Sin Young Kim"
    },
    {
      "affs": [
        2
      ],
      "name": "Seo Kyung An"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Dong Gyu Na"
    },
    {
      "affs": [
        5
      ],
      "name": "Young Ju Kim"
    },
    {
      "affs": [
        5
      ],
      "name": "Kichang Kwak"
    },
    {
      "affs": [
        0,
        1,
        5
      ],
      "name": "Sang Won Seo"
    },
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Duk L Na",
      "orcid": "0000-0002-0098-7592"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3btc0sqnr83vx.bib",
  "cited_by": 0,
  "doi": "10.1002/dad2.70473",
  "fulltext_url": "https://europepmc.org/articles/PMC13683556",
  "id": "3btc0sqnr83vx",
  "issns": [
    "2352-8729"
  ],
  "landing_url": "https://europepmc.org/article/MED/42908770",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2737|Alzheimer's disease research and treatments"
    ]
  ],
  "openalex": "W7223049904",
  "pdf_url": "https://europepmc.org/articles/PMC13683556?pdf=render",
  "pmcid": "PMC13683556",
  "pmid": "42908770",
  "published": "2026-10-20",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/3btc0sqnr83vx.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:10Z",
      "native_id": "MED:42908770",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42908770"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Alzheimer's disease research and treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Topography and risk factors of amyloid-related imaging abnormality: real-world data from 168 aducanumab-treated patients at a private clinic in South Korea.",
  "title_text": "Topography and risk factors of amyloid-related imaging abnormality: real-world data from 168 aducanumab-treated patients at a private clinic in South Korea.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:10Z",
  "url": "https://research.draconitic.com/paper/3btc0sqnr83vx",
  "venue": "Alzheimer's & dementia (Amsterdam, Netherlands)",
  "versions": []
}